A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma

What is the purpose of this trial?

This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose, dose-escalation, safety, PK, and PD study of ALX148. The phase 1 protocol will have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase (Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion portion. Approximately 110 adult patients are expected to be enrolled in the study.



Alexo Therapeutics Inc.

Dates: 07/21/2017 - 01/01/2019

Last Updated: 07/23/2017

Study HIC#: 2000020159

Get Involved

For more information about this study, contact:
Jacqueline Rollin
203-859-0001
jacqueline.rollin@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image